Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis

The laboratory evaluation of cerebrospinal fluid (CSF) has been routinely employed as a diagnostic test in the diagnosis of neuroimmunological disorders such as multiple sclerosis (MS). Recently, CSF analyses in MS have garnered renewed interest as a tool for monitoring disease activity and prognosis. With the identification of patients that are very early in their disease course, namely patients with a radiologically isolated (RIS) or a clinically isolated syndrome (CIS), the true value of these evaluations has yet to be fully explored. Ultimately, the hope is that biomarkers within this compartment will be identified that will identify etiologic factors of MS and other inflammatory disorders of the central nervous system. In this review we discuss the history of CSF diagnostic tests and the most recent methodological advances. We also outline the potentially important diagnostic role and possible limitations of these tests.

[1]  T. J. Murray Multiple Sclerosis: The History of a Disease , 2004 .

[2]  T. Brücke,et al.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis , 2008, Journal of Neurology.

[3]  D. Keren Optimizing detection of oligoclonal bands in cerebrospinal fluid by use of isoelectric focusing with IgG immunoblotting. , 2003, American journal of clinical pathology.

[4]  K. Nékám,et al.  Concentration of Soluble Adhesion Molecules (sVCAM-1, sICAM-1 and sL-Selectin) in the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis and Systemic Lupus erythematosus with Central Nervous Involvement , 2001, Neuroimmunomodulation.

[5]  J. Losy,et al.  Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients. , 2001, Folia neuropathologica.

[6]  J. Correale,et al.  Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS , 2003, Journal of Neuroimmunology.

[7]  H. Reiber,et al.  Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[8]  A. Minagar,et al.  Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study , 2005, Journal of Neuroinflammation.

[9]  A. Rovira,et al.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.

[10]  D. Miller,et al.  Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.

[11]  Michael J. Ramsbottom,et al.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients , 2006, Journal of Neuroimmunology.

[12]  W. Tourtellotte,et al.  Schemes to eradicate the multiple sclerosis central nervous system immune reaction , 1976, Neurology.

[13]  D. Freedman,et al.  The cerebrospinal fluid in multiple sclerosis. , 1934, Research publications - Association for Research in Nervous and Mental Disease.

[14]  H. Tumani,et al.  Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis , 2006, Multiple sclerosis.

[15]  D. Hafler,et al.  Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid , 2009, Annals of neurology.

[16]  W. Tourtellotte,et al.  Immunoglobulin heavy chain associated protein in multiple sclerosis cerebrospinal fluid. , 1986, Molecular immunology.

[17]  C. Granger,et al.  Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1 , 1999, Journal of Neuroimmunology.

[18]  M. Reindl,et al.  Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  B. Weinshenker,et al.  Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Isoelectric focusing with IgG immunoblotting compared with high-resolution agarose gel electrophoresis and cerebrospinal fluid IgG index. , 2003, American journal of clinical pathology.

[20]  H. Reiber External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. , 1995, Clinical chemistry.

[21]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[22]  L. Villar,et al.  Multiple sclerosis patients with anti‐lipid oligoclonal IgM show early favourable response to immunomodulatory treatment , 2009, European journal of neurology.

[23]  E. Kabat,et al.  AN ELECTROPHORETIC STUDY OF THE PROTEIN COMPONENTS IN CEREBROSPINAL FLUID AND THEIR RELATIONSHIP TO THE SERUM PROTEINS. , 1942, The Journal of clinical investigation.

[24]  E. Bock,et al.  N-CAM in cerebrospinal fluid: a marker of synaptic remodelling after acute phases of multiple sclerosis? , 1987, Italian journal of neurological sciences.

[25]  N. Gilhus,et al.  Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force , 2006, European journal of neurology.

[26]  S. Takahashi,et al.  Hashimoto encephalopathy: etiologic considerations. , 1994, Pediatric neurology.

[27]  Z. Stelmasiak,et al.  Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients , 2005, Journal of Neural Transmission.

[28]  C. Polman,et al.  Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients , 2003, Neuroscience Letters.

[29]  M. Sharief,et al.  Significance of CSF immunoglobulins in monitoring neurologic disease activity in Behçet's disease , 1991, Neurology.

[30]  K. Trinkaus,et al.  Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis , 2006, Neurology.

[31]  E. İdiman,et al.  Intrathecal sICAM-1 production in multiple sclerosis Correlation with triple dose Gd-DTPA MRI enhancement and IgG index , 2005, Journal of Neurology.

[32]  G. Bernardi,et al.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[33]  H. Reiber,et al.  The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis , 1998, Multiple sclerosis.

[34]  E. Merelli,et al.  A multifactorial prognostic index in multiple sclerosis , 2008, Journal of Neurology.

[35]  T. Marra Multiple Sclerosis with Onset after Age 60 , 1984, Journal of the American Geriatrics Society.

[36]  David H. Miller,et al.  Lack of association between antimyelin antibodies and progression to multiple sclerosis. , 2007, The New England journal of medicine.

[37]  E. Thompson,et al.  A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. , 1990, Brain : a journal of neurology.

[38]  J. Hillert,et al.  Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis , 2002, Neuroscience Letters.

[39]  L. Wahlund,et al.  Diagnostic use of cerebral and extracerebral oxysterols , 2004, Clinical chemistry and laboratory medicine.

[40]  G. McDonnell,et al.  Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis , 1998, Journal of Neuroimmunology.

[41]  I. Steiner,et al.  Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions. , 2000, Archives of neurology.

[42]  T. Rosenberg,et al.  Leber's hereditary optic neuropathy associated with a disorder indistinguishable from multiple sclerosis in a male harbouring the mitochondrial DNA 11778 mutation , 1995, Acta neurologica Scandinavica.

[43]  H. Hartung,et al.  Cerebrospinal fluid biomarkers in multiple sclerosis , 2009, Neurobiology of Disease.

[44]  Z. Sučić,et al.  Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. , 2002, Cytokine.

[45]  Y Ben-Shlomo,et al.  CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[46]  Helena Chmura Kraemer,et al.  Evaluating Medical Tests: Objective and Quantitative Guidelines , 1992 .

[47]  J. Masjuán,et al.  Clinically isolated syndromes , 2006, Neurology.

[48]  S. Cepok,et al.  Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.

[49]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[50]  M. Trojano,et al.  Cerebrospinal Fluid Analysis in Multiple Sclerosis , 1996, Springer Milan.

[51]  W. Poewe,et al.  Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. , 1999, Brain : a journal of neurology.

[52]  L. Rosengren,et al.  Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit , 1995, Journal of the Neurological Sciences.

[53]  C. R. Snyder,et al.  Cerebrospinal fluid analysis in human immunodeficiency virus infection. , 1992, Annals of clinical and laboratory science.

[54]  B. Tavolato,et al.  Free light chains in the CSF in multiple sclerosis , 1987, Journal of Neurology.

[55]  Y. Qin,et al.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. , 1998, The Journal of clinical investigation.

[56]  K. Nékám,et al.  Increased levels of tumor necrosis alpha and soluble vascular endothelial adhesion molecule-1 in the cerebrospinal fluid of patients with connective tissue diseases and multiple sclerosis. , 2003, Acta microbiologica et immunologica Hungarica.

[57]  A. Bar-Or,et al.  Do myelin-directed antibodies predict multiple sclerosis? , 2003, The New England journal of medicine.

[58]  J. Ernerudh,et al.  Improved Formulae for the Judgement of Intrathecal Produced IgA and IgM in the Presence of Blood CSF Barrier Damage , 1993, Annals of clinical biochemistry.

[59]  D. Lütjohann,et al.  Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.C400005-JLR200 , 2005, Journal of Lipid Research.

[60]  V. Leoni Oxysterols as markers of neurological disease – a review , 2009, Scandinavian journal of clinical and laboratory investigation.

[61]  D. Gilden,et al.  Comparative Analysis of the CD19+ and CD138+ Cell Antibody Repertoires in the Cerebrospinal Fluid of Patients with Multiple Sclerosis1 , 2004, The Journal of Immunology.

[62]  G. Aimard,et al.  Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[63]  E. Thompson,et al.  The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis , 1991, Annals of neurology.

[64]  D. Hafler,et al.  Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein1 , 2005, The Journal of Immunology.

[65]  J. Bennett,et al.  B‐lymphocyte and plasma cell clonal expansion in monosymptomatic optic neuritis cerebrospinal fluid , 2004, Annals of neurology.

[66]  A. Vighetto,et al.  Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. , 2001, Archives of neurology.

[67]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[68]  M. Filippi,et al.  Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients , 1993, Journal of Neuroimmunology.

[69]  P. Rieckmann,et al.  Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis , 1998, Multiple sclerosis.

[70]  N. Yanagisawa,et al.  Increased levels of soluble vascular cell adhesion molecule-1 ( VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy , 1995, Journal of Neuroimmunology.

[71]  M. Hennerici,et al.  Vascular cell adhesion molecule — a new approach to detect endothelial cell activation in MS and encephalitis in vivo , 1996, Acta neurologica Scandinavica.

[72]  J. Bennett,et al.  Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis , 2009, Journal of Neuroimmunology.

[73]  F. Deisenhammer,et al.  Correlation between the IgG index, oligoclonal bands in CSF, and the diagnosis of demyelinating diseases , 2005, European journal of neurology.

[74]  S. Sorbi,et al.  The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis , 2009, Multiple sclerosis.

[75]  C. Granger,et al.  Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. , 1999, Journal of neuroimmunology.

[76]  J. Frederiksen,et al.  The cerebrospinal fluid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae , 1996 .

[77]  J. Bennett,et al.  CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome , 2008, Journal of Neuroimmunology.

[78]  D. Gilden,et al.  Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.

[79]  E. Thompson,et al.  Short communication CNS tumours: oligoclonal immunoglobulin D in cerebrospinal fluid and serum , 1999, Acta neurologica Scandinavica.

[80]  J. Fischer,et al.  Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains , 1995, Multiple sclerosis.

[81]  C. Polman,et al.  Biological markers in CSF and blood for axonal degeneration in multiple sclerosis , 2005, The Lancet Neurology.

[82]  A. Bar-Or,et al.  Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis , 2006 .

[83]  F. Barkhof,et al.  Multiple sclerosis , 2003, Neurology.

[84]  E. Byrne,et al.  Symptomatic female heterozygotes for adrenoleukodystrophy: A report of two unrelated cases and review of the literature , 1996, Journal of clinical neuroscience.

[85]  J. Gómez-Rial,et al.  CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis , 2009, Journal of Neuroimmunology.

[86]  R. Shenkar,et al.  Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. , 2007, Journal of neurosurgery.

[87]  N. Scolding,et al.  Neurosarcoidosis: a study of 30 new cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[88]  S. Poser,et al.  Age at onset, initial symptomatology and the course of multiple sclerosis , 1982, Acta neurologica Scandinavica.

[89]  U. Bogdahn,et al.  Borrelia burgdorferi—specific and autoreactive T‐cell lines from cerebrospinal fluid in lyme radiculomyelitis , 1988, Annals of neurology.

[90]  S. Hawkins,et al.  Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1 , 1996, Journal of Neuroimmunology.

[91]  C. Laurell,et al.  Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation. , 1974, Clinical chemistry.

[92]  Roland Martin,et al.  Virus-specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitis☆ , 1989, Journal of Neuroimmunology.

[93]  Z. Sfaello,et al.  Electrophoretic morphology of gamma globulins in cerebrospinal fluid of multiple sclerosis and other diseases of the nervous system , 1970, Neurology.

[94]  J. Ernerudh,et al.  Comparison of Seven Formulae and Isoelectrofocusing for Determination of Intrathecally Produced IgG in Neurological Diseases , 1992, Annals of clinical biochemistry.

[95]  I. Catz,et al.  A myelin basic protein antibody cascade in purified IgG from cerebrospinal fluid of multiple sclerosis patients , 1990, Journal of the Neurological Sciences.

[96]  H. Ulmer,et al.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. , 2003, The New England journal of medicine.

[97]  A. Carpentier,et al.  Cerebrospinal fluid study in paraneoplastic syndromes , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[98]  J. Bednářová Cerebrospinal-fluid profile in neuroborreliosis and its diagnostic significance , 2008, Folia Microbiologica.

[99]  K. Nékám,et al.  Soluble L‐selectin levels in serum and cerebrospinal fluid in patients with multiple sclerosis and systemic lupus erythematosus , 2000, Acta neurologica Scandinavica.

[100]  M. Freedman,et al.  The prognostic significance of cerebrospinal fluid in multiple sclerosis , 2009, Journal of the Neurological Sciences.

[101]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[102]  A. Salmaggi,et al.  Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients , 1998, Journal of Neuroimmunology.

[103]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[104]  K. Nékám,et al.  A study of increased levels of soluble vascular cell adhesion molecule‐1 (SVCAM‐1) in the cerebrospinal fluid of patients with multiple sclerosis and systemic lupus erythematosus , 1999, Acta neurologica Scandinavica.

[105]  G. McDonnell,et al.  Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. , 2000, Acta neurologica Scandinavica.

[106]  F. Bouwman,et al.  Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis , 2009, Neurology.

[107]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[108]  L. Fratiglioni,et al.  Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis , 1991, Acta neurologica Scandinavica.

[109]  M. Spiegel-Adolf,et al.  Cerebrospinal fluid. , 1965, Progress in neurology and psychiatry.

[110]  H. Merritt,et al.  The cerebrospinal fluid , 1938 .

[111]  S. West,et al.  Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. , 1995, The American journal of medicine.

[112]  P. Forsberg,et al.  An improved formula for the judgement of intrathecally produced IgG in the presence of blood brain barrier damage. , 1989, Clinica chimica acta; international journal of clinical chemistry.

[113]  P. Narayana,et al.  Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.

[114]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[115]  C. Lombard,et al.  Diagnostic et surveillance biologique de six neurosyphilis : apport de l’étude du liquide céphalorachidien , 2003 .

[116]  P. Vermersch,et al.  Neurologic Manifestations in Primary Sjögren Syndrome: A Study of 82 Patients , 2004, Medicine.

[117]  P. Mehta,et al.  Absence of oligoclonal IgA in CSF and serum of multiple sclerosis patients , 1984, Journal of Neuroimmunology.